Loading...
Phase I Evaluation of ΔvirG Shigella sonnei Live, Attenuated, Oral Vaccine Strain WRSS1 in Healthy Adults
Kotloff, Karen L. Taylor, David N. Sztein, Marcelo B. Wasserman, Steven S. Losonsky, Genevieve Katz, David E. Campbell, James D. Levine, Myron M. Hale, Thomas L.
Kotloff, Karen L.
Taylor, David N.
Sztein, Marcelo B.
Wasserman, Steven S.
Losonsky, Genevieve
Katz, David E.
Campbell, James D.
Levine, Myron M.
Hale, Thomas L.
Citations
Altmetric:
Abstract
We conducted a phase I trial with healthy adults to evaluate WRSS1, a live, oral ΔvirG Shigella sonnei vaccine candidate. In a double-blind, randomized, dose-escalating fashion, inpatient volunteers received a single dose of either placebo (n = 7) or vaccine (n = 27) at 3 × 103 CFU (group 1), 3 × 104 CFU (group 2), 3 × 105 CFU (group 3), or 3 × 106 CFU (group 4). The vaccine was generally well tolerated, although a low-grade fever or mild diarrhea occurred in six (22%) of the vaccine recipients. WRSS1 was recovered from the stools of 50 to 100% of the vaccinees in each group. The geometric mean peak anti-lipopolysaccharide responses in groups 1 to 4, respectively, were 99, 39, 278, and 233 for immunoglobulin (IgA) antibody-secreting cell counts; 401, 201, 533, and 284 for serum reciprocal IgG titers; and 25, 3, 489, and 1,092 for fecal IgA reciprocal titers. Postvaccination increases in gamma interferon production in response to Shigella antigens occurred in some volunteers. We conclude that WRSS1 vaccine is remarkably immunogenic in doses ranging from 103 to 106 CFU but elicits clinical reactions that must be assessed in further volunteer trials.
Description
Date
2002-04
Journal Title
Journal ISSN
Volume Title
Publisher
American Society for Microbiology
Collections
Files
Loading...
Picking_2002.pdf
Adobe PDF, 132.37 KB
Research Projects
Organizational Units
Journal Issue
Keywords
Citation
Kotloff, K. L., Taylor, D. N., Sztein, M. B., Wasserman, S. S., Losonsky, G. A., Nataro, J. P., … Hale, T. L. (2002). Phase I Evaluation of ΔvirG Shigella sonnei Live, Attenuated, Oral Vaccine Strain WRSS1 in Healthy Adults . Infection and Immunity, 70(4), 2016–2021. http://doi.org/10.1128/IAI.70.4.2016-2021.2002